Aditxt, Inc. - ADTX STOCK NEWS

Aditxt (NASDAQ: ADTX) announced a significant milestone in its acquisition plans for Appili Therapeutics (TSX: APLI; OTCPink: APLIF). At a special meeting, Appili's shareholders voted overwhelmingly in favor of a plan of arrangement that would allow Aditxt to acquire all issued and outstanding Class A common shares of Appili. This development marks a important step forward in Aditxt's strategy to expand its healthcare innovation platform.

Evofem Biosciences (OTCQB: EVFM) has secured voting agreements with Series E-1 stockholders and convertible noteholders to support its proposed merger with Aditxt's subsidiary Adifem. This follows Aditxt's recent $2.28 million investment in Evofem through Series F-1 convertible preferred stock, completing their total $5.0 million commitment since May 2024. The merger's closing conditions include majority shareholder approval and Aditxt raising approximately $17 million, with $15.2 million needed to satisfy Evofem's senior secured noteholder. The capital received has enabled Evofem to acquire SOLOSEC® and support Phexxi® initiatives targeting GLP-1 users.

Aditxt (NASDAQ: ADTX) has announced a significant development regarding its target acquisition, Appili Therapeutics (TSX: APLI; OTCPink: APLIF). The U.S. Food and Drug Administration (FDA) has provided positive feedback on the development strategy for ATI-1801, Appili's topical antiparasitic product. This feedback aligns with the requirements for the New Drug Application (NDA) submission.

Aditxt (NASDAQ: ADTX) has announced a virtual fireside chat on October 28, 2024, at 11:30 AM ET, featuring Aditxt CEO Amro Albanna, Evofem CEO Saundra Pelletier, and moderated by Dr. Drew Pinsky. The event will focus on:

• Aditxt's acquisition of Evofem
• Post-acquisition plans for Evofem
• Aditxt's approach to accelerating innovations

The chat will highlight Evofem's evolution into a multi-product women's health franchise, including the re-launch of Solosec® and the planned launch of the Mitomic Endometriosis Test (MET™) in mid-2025. Aditxt estimates it will require $19.3 million to fund the Evofem acquisition, including $1.8 million for merger consideration and $2.28 million for additional Evofem stock purchase by October 31, 2024. An additional $15.2 million is needed to satisfy Evofem's Senior Secured Note at closing.

Aditxt (NASDAQ: ADTX) announced that Appili Therapeutics (TSX: APLI; OTCPink: APLIF) will hold a special meeting on November 6, 2024, for shareholders to vote on Aditxt's proposed acquisition. Appili's board recommends voting in favor. Appili has raised CAD $100M for developing infectious disease and biodefense therapeutics. Its portfolio includes:

1. LIKMEZ™: FDA-approved liquid antibiotic

2. ATI-1701: Tularemia vaccine with $14M in funding

3. ATI-1801: Topical treatment for cutaneous leishmaniasis

Two programs may be eligible for FDA Priority Review Vouchers. The acquisition aims to expand Aditxt's reach in addressing infectious diseases and public health challenges.

Aditxt (NASDAQ: ADTX) has announced a stakeholder update and Q&A session scheduled for Friday, October 11, 2024, at 11:30 AM EDT. CEO Amro Albanna will lead the session, covering:

• Company overview and updates on Evofem and Appili transactions
• Current programs in immune and precision health
• Year-end roadmap for 2024
• Q&A segment addressing pre-submitted questions

Aditxt operates two programs focused on immune health and precision health, with plans to introduce two additional programs in public health and women's health. The company has entered into agreements with Appili Therapeutics and Evofem Biosciences for these new programs. Aditxt's innovation platform aims to accelerate promising health innovations through collaboration with research institutions, industry partners, and shareholders.

Aditxt (NASDAQ: ADTX) has completed the Third Parent Equity Investment in Evofem Biosciences (OTCQB: EVFM) under their Amended and Restated Merger Agreement. Aditxt purchased 460 shares of Evofem Series F-1 Convertible Preferred Stock for $460,000, bringing their total investment to $1.72 million. Aditxt plans to complete the Fourth Parent Equity Investment of $2.28 million by October 31, 2024.

Evofem has expanded from a single-product company to offering diversified solutions in women's health, including Phexxi (contraceptive gel) and SOLOSEC (antibiotic). They are preparing to launch the Mitomic Endometriosis Test in mid-2025 and have signed a licensing agreement with Pharma 1 Drug Store to bring Phexxi to the Gulf Cooperation Council region.

Aditxt aims to accelerate innovative health companies through its business platform, which includes subsidiaries Adimune (immune health) and Pearsanta (precision health). Both companies believe the merger will strengthen Evofem's ability to expand access to women's health products globally.

Aditxt, Inc. (NASDAQ: ADTX) has announced a 1-for-40 reverse stock split effective at the open of trading on October 2, 2024. The company's common stock will continue to trade under the symbol ADTX on the Nasdaq Capital Market. This decision was approved by stockholders on August 7, 2024, with the final ratio determined by the board of directors.

Key points:

• New CUSIP number: 007025703
• Every 40 shares will be exchanged for 1 share
• Fractional shares will be rounded up
• Post-split: approximately 244,667 shares outstanding

The primary goal of this reverse split is to bring Aditxt into compliance with Nasdaq's minimum bid price requirement. More information can be found in the company's definitive proxy statement filed on July 5, 2024.

Aditxt, Inc. (NASDAQ: ADTX) announced that its acquisition target, Evofem Biosciences, Inc. (OTCQB: EVFM), has filed a preliminary proxy to seek stockholder approval for the merger outlined in the Amended and Restated Merger Agreement dated July 12, 2024. The agreement involves Adifem, Inc., a wholly-owned subsidiary of Aditxt, merging with Evofem, resulting in Evofem becoming a wholly-owned subsidiary of Aditxt.

The companies are targeting to close the transaction in the fourth quarter of 2024, subject to Evofem stockholder approval and other closing conditions, including Aditxt raising sufficient capital to fund its obligations at closing. However, no assurance is provided that all conditions will be met or that the transaction will ultimately close.